What Medicares Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries The Centers for Medicare & Medicaid Services (CMS) has released a memo fleshing out the design of a short-term program providing Medicare coverage of GLP-1s for obesity in 2026 ahead of a multi-year demonstration program beginning in 2027
Additionally, atrophic gastritisaffecting 1030% of people over 50impairs intrinsic factor production
This treatment aims to improve chronic pain (lasting from several months to years)
Protein-rich regimens have taken off after millions of Americans found that stocking their pantries with supposedly "heart-healthy" snacks such as granola bars and fruit juice failed to improve wellness
Nevertheless, considerable interindividual variability in weight gain responses highlights a likely genetic componenttwin and sibling studies, as well as genome-wide association studies (GWAS), consistently demonstrate a heritable component to antipsychotic-induced weight gain, with specific single nucleotide polymorphisms in genes such as HTR2C, MC4R, BDNF, DRD2, ADRA2A, INSIG2, CNR1, and others showing significant associations with increased risk and greater magnitude of weight gain (Sicard et al
